Home MarketSyngene International Ltd.

Syngene International Ltd. Stock Info: As on 2018-02-22 15:59:45

Nse

572.95

-7.90(-1.36%)
Change%
52 Week Range
430.10
11.00
672.00
24.00
Open575.05
Day's Range464.68 - 697.02
Value Traded (in ₹ Cr.) 2.80

Bse

568.45

-11.70(-2.02%)
Change %
52 Week Range
430.00
11.00
670.00
24.00
Open578.40
Day's Range464.12 - 696.18
Value Traded (in ₹ Cr.) 0.62

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 148,927,671.00 74.46%
Mutual Funds/UTI 5,018,948.00 2.51%
FII 30,330,951.00 15.17%
Employee 0.00 0.00%
Public 9,460,881.00 4.73%
Government 0.00 0.00%
Others 2,744,112.00 1.37%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 6.91
Basic EPS (Rs.) 11.40
Cash EPS 15.99
BVPerShare Excl 52.85
Operating Revenue 55.57
PBDITPerShare 18.27
Dividend 1.00
NPPerShare 11.10
Current Ratio 2.52
Quick Ratio 2.45
PriceToBV 7.27
Earnings 0.02
PBDIT Margin 32.87
PBT Margin 23.32
NP Margin 19.98
Return On Assets 9.25
Retention Ratios 90.95
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 1,113.10
Total Expenses 854.90
EBITDA 363.90
PBT 258.20
PAT 221.20
Net Income 221.20
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 614.90
Total Expenses 466.10
EBITDA 97.50
PBT 146.60
PAT 125.30
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 199.20
Net worth 1,052.80
Investments 276.40
Total Liability 2,389.50
Total debt 891.00
Net block 817.00
Total Assets 2,389.50
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 199.20
Net worth 1,052.80
Investments 276.40
Total Liability 2,389.50
Total debt 891.00
Net block 817.00
Total Assets 2,389.50
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

404 395.6 2.12
387.2424

Banaras Beads Ltd.

67.9 65.1 4.3
61.1571.5

Binani Industries Ltd.

103.95 107.15 -2.99
105118.25

Career Point Ltd.

124.35 123.55 0.65
123.15138.6

Delta Corp Ltd.

348.9 352.2 -0.94
349386.4

Dredging Corporation Of India Ltd.

689 686.95 0.3
678.75737.8

Future Consumer Ltd.

60.25 59.9 0.58
58.1563.75
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

404.1 395.55 2.16
387.4423.85

Alpha Hi-Tech Fuel Ltd.

0.87 0.91 -4.39
0.870.87

Anil Ltd.

28.9 30.4 -4.93
28.928.9

Bagalkot Udyog Ltd.

23.9 25.15 -4.97
23.923.9

Banaras Beads Ltd.

68.15 65 4.85
61.568.5

Binani Industries Ltd.

104 107.5 -3.26
105.4119.2

Brahmanand Himghar Ltd.

4.08 4.29 -4.9
4.084.08
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 312.40
Cash from investing activities -748.80
Cash from financing activities 709.40
Net change in cash 271.60

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Reliance Regular Savings Fund - Equity 1.90%
UTI Mid Cap Fund 1.43%
Motilal Oswal Most Focused Long Term Fund 2.92%
Canara Robeco Emerging Equities 0.74%
Motilal Oswal MOSt Focused Dynamic Equity Fund 1.31%
Reliance Pharma Fund 0.56%

Tata Comm partners Chunghwa telecom to provide IoT experience

Tata Communications, a leading digital infrastructure provider has said that it is joining forces with Chunghwa Telecom, Taiwan’s largest mobile network operator, to bring global connectivity to consumer electronics and industrial Internet of Things (IoT) devices. Tata Communications MOVE - IoT Connect™ allows IoT devices to be deployed quickly both locally and internationally by leveraging Tata Communications’ ecosystem of mobile network operators worldwide. As part of this ecosystem, Chunghwa Telecom will be able to tap into additional revenues by connecting IoT devices through Tata Communications MOVE™. The Taiwanese electronics industry output is expected to be worth USDD 228 billion (NT$6.65 trillion) in 2018, and the wearables market grew at double digits in both volume and value terms in 2017. Chunghwa Telecom looks to capitalise on this growth through the existing IoT roaming services it provides, and by offering its device manufacturer and enterprise customers’ IoT services instant global reach through Tata Communications MOVE - IoT Connect™. Meanwhile, shares of the company were trading at Rs 629 apiece, up 0.58 per cent from the previous close at 10:09 hours on BSE.

22-02-2018 10:01

Godrej Properties adds new residential project in Gurgaon

Godrej Properties Ltd. (GPL), one of India’s leading real estate developers has said that it has expanded its residential portfolio in NCR, with an addition of a new residential project in Gurgaon. This project will offer approximately 70,500 square meters (approximately 7.5 lakh sq. ft.) of saleable area and will be developed as a modern group housing development. This project is situated in an established location within Gurgaon City and has excellent connectivity to the various key micro-markets in Gurgaon. This is GPL’s twelfth project within the National Capital Region (NCR). Within five years of entering the NCR market, Godrej Properties has established itself as one of the market leaders in NCR and hopes to further build on this position. Meanwhile, shares of the company were trading at Rs 773 apiece, up 0.13 per cent from the previous close at 09:27 hours on BSE.

22-02-2018 09:20

Glenmark Pharma enters into agreement with Sam Chun Dang

Glenmark Pharmaceuticals, a global pharmaceutical company has said that it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. Ltd. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America. It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the U.S. brand sales for the six products was approximately $1.7 billion for calendar year 2017. Meanwhile, shares of the company were trading at Rs 524 apiece, down 0.13 per cent from the previous close at 09:27 hours on BSE.

22-02-2018 09:19

Allahabad Bank has Rs 517-cr exposure to Rotomac

State-owned Allahabad Bank today said it has an exposure of Rs 516.79 crore to crisis-hit Rotomac group and the lender has made required provisioning for the same as per RBI norms, reported PTI. Responding to a clarification sought by exchanges on news article Rotomac owner flees India after taking Rs 800 crore loans', the Allahabad Bank said the group is having an exposure from our bank since 2006. There is an outstanding of Rs 43.09 crore to Rotomac Exim Pvt Ltd as a sole banker, Rs 314.56 crore to Rotomac Global as multiple banking lending and Rs 159.14 crore to Rotomac Exports as a consortium arrangement with Bank of India as a lead banker. These three loans amount to Rs 516.79 crore. The aforesaid accounts of Rotomac group classified as non-performing assets as per IRAC norms of RBI and the required provision has been made, it said in a regulatory filing. The bank said the accounts of Rotomac Global and Rotomac Exports have been filed in National Company Law Tribunal (NCLT) and was admitted on September 20, 2017. The recovery process under SARFAESI is in process by the bank for the third Rotomac group company, namely, Rotomac Exim Pvt Ltd, it said. A number of banks have made announcements to the stock exchanges clarifying on the news since their names have appeared in the news item earlier this week. Bank of Baroda has an exposure to the tune of 456.60 crore to Rotomac group companies that it declared as bad loans in October 2015 and has already started recovery process by registering the case under Corporate Insolvency Resolution Process at NCLT. Besides, Bank of India, Union Bank of India and Indian Overseas Bank also have their respective exposures to the Rotomac group and they have resorted to the available mechanisms to recover their dues. After the enactment of Insolvency and Bankruptcy Code in 2016, the banks have started going to corporate insolvency resolution process to recover their dues from borrowers. Complaints have already being lodged with the CBI, ED and Directorate of Revenue Intelligence against the Rotomac group. After the CBI and ED, the Income Tax Department has stepped up action against Kanpur-based Rotomac group and its promoter, attaching 11 bank accounts in connection with an alleged tax evasion probe against them.. The accounts of the group in various bank branches in Uttar Pradesh have already been attached by the agencies.

22-02-2018 00:50

Kothari Indl. posts Q3 net loss of Rs 0.78 cr

The company reported standalone net loss during the quarter stood at Rs 0.78 crore as compared to net loss of Rs 0.27 crore in the previous year quarter. Net revenue of the company declined substantially by 29.70 per cent at Rs 7.55 crore in October-December quarter of this fiscal as against Rs 10.74 crore in the corresponding period last year. During October-December quarter, operating expenses dropped by 23.56 per cent to Rs 7.98 crore from Rs 10.44 crore in year ago period. Other Income grew by 47.83 per cent at Rs 0.68 crore versus (Dec'16 Rs 0.46 crore). Operating Profit slipped by 243.33 per cent to Rs -0.43 crore as against Rs 0.30 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 302.87 per cent in December quarter.

21-02-2018 17:05

Syngene Internationa - Analysts/Institutional Investor Meet/Con. Call Updates

Syngene International Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

16-Feb-2018 02:14 PM

Syngene Internationa - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation of schedule of meetings with Analyst/Institutional Investor

16-Feb-2018 02:11 PM

Syngene Internationa - Analysts/Institutional Investor Meet/Con. Call Updates

Syngene International Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

02-Feb-2018 03:13 PM

Syngene Internationa - Analyst / Investor Meet - Intimation

Analyst/Investor Meet

02-Feb-2018 03:10 PM

Syngene Internationa - Investor Presentation

Syngene International Limited has informed the Exchange regarding Investor Presentation

24-Jan-2018 03:33 PM

Syngene Internationa - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation of schedule of meetings with Analyst/Institutional Investor

16-Feb-2018 02:11 PM

Syngene Internationa - Analyst / Investor Meet - Intimation

Analyst/Investor Meet

02-Feb-2018 03:10 PM

Syngene Internationa - Investor Presentation

This has reference to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the Investor Presentation for the quarter ended December 31, 2017. The company will use this presentation for any meeting scheduled with analysts or institutional investors up to March 31, 2018.

24-Jan-2018 03:31 PM

Corporate Details

About Management

The Company was incorporated as Syngene International Private Limited on November 18, 1993 at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. Pursuant to a special resolution of the shareholders dated March 26, 2007, the Company was converted into a public limited company and the name of the Company was changed to Syngene International Limited. A fresh certificate of incorporation consequent upon conversion to public limited company was issued on April 19, 2007. the Company was promoted by Kiran Mazumdar Shaw, a promoter of Biocon. On March 30, 2002, 99.9 percent of the Equity Shares of the Company were transferred to Biocon and as a result, the Company became the subsidiary of Biocon. Biocon has since been the Promoter of the Company.The details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Special Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099, Karnataka, India. Major events and milestones of the Company : 1994 -Initiated operations as a CRO with services in chemistry and biology 1998 -Granted 100% Export Oriented Unit (EOU) status by the Government of India 1999 -First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft. 2000 -CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies 2001 -Forayed into chemical development with a dedicated manufacturing facility 2003 -Moved to Biocon Park, a 90 acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft. 2007 -Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D centre -Expansion of research facilities at Biocon SEZ to 148,000 sq. ft. -Crossed an annual turnover of over `1,000 million in Financial Year 2007 2009 -Dupont Crop Protection and the Company extended a partnership for R&D services -Expansion of manufacturing services with a new plant which is cGMP compliant -Initiated operations in safety assessment and large molecules development services 2010 -Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA -Initiated operations in formulation development 2011 -Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer 2012 -Abbott and the Company collaborated to establish Abbott's nutrition research and development centre in India and the second R&D centre -Certification of the clinical facilities by ANVISA -Acquired 100% stake in Clinigene International Limited from Biocon 2013 -Crossed an annual turnover of over `5,000 million in Financial Year 2013 -Baxter International Inc. collaborated with the Company to establish the `Baxter Global Research Center', the third dedicated R&D centre -Acceptance of the control testing laboratory by the Department of Health & Human Services, FDA 2014 -Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D centre till 2020 -Acceptance of the API manufacturing facility by the Department of Health & Human Services, FDA -Established a 75,000 sq.ft centre to provide stability and analytical services 2015 -CIL was amalgamated with the Company Awards, Recognitions and Accreditations : 2009 - Bangalore Bio, Bio Excellence Award - Biotech Services Sector - Best BioServices company of the year by Biospectrum 2012 - ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - AAALAC accreditation for conforming to the "Guide for the Care and Use of Laboratory Animals and the Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines" 2013 - Bioservices - ABLE Tenth Anniversary Award - Outstanding contribution to Bioservices - Diamond sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology 2014 - ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - Silver EDGE Award - EHS best practices award by CII - SAP Ace Award for special recognition for complex SAP implementation - Level I Laboratory certification issued by the NGSP to Clinigene International Limited 2015 - Accreditation by the College of American Pathologists in relation to their laboratory accreditation program - Bangalore India Bio - Bio Excellence Award for outstanding contribution to the Biotech services sector - ISO 15189:2007 in the field of medical testing

Registered Office

113-C - 2, Bommasandra Industrial Area, Attibele Hobli, Anekal Taluk,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.